{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:31:19Z","timestamp":1784233879818,"version":"3.55.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jcrc.2025.155077","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T19:12:36Z","timestamp":1744312356000},"page":"155077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Enibarcimab for the treatment of septic shock in patients selected by a combination of the biomarkers bio-ADM and DPP3: A prespecified subgroup analysis of the AdrenOSS-2 trial"],"prefix":"10.1016","volume":"88","author":[{"given":"Claudia","family":"Knothe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Francois","family":"Laterre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pickkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jcrc.2025.155077_bb0005","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcrc.2025.155077_bb0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s13054-018-2243-2","article-title":"Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and outcome in Sepsis and septic Shock-1 (AdrenOSS-1) study","volume":"22","author":"Mebazaa","year":"2018","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.jcrc.2025.155077_bb0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/SHK.0000000000001103","article-title":"Vascular effects of Adrenomedullin and the anti-Adrenomedullin antibody Adrecizumab in Sepsis","volume":"50","author":"Geven","year":"2018","journal-title":"Shock"},{"issue":"1","key":"10.1016\/j.jcrc.2025.155077_bb0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13054-018-2074-1","article-title":"The mechanism of action of the adrenomedullin-binding antibody adrecizumab","volume":"22","author":"Geven","year":"2018","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.jcrc.2025.155077_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024475","volume":"9","author":"Geven","year":"2019","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.jcrc.2025.155077_bb0030","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3343\/alm.2019.39.5.454","article-title":"Circulating biologically active Adrenomedullin predicts organ failure and mortality in Sepsis","volume":"39","author":"Kim","year":"2019","journal-title":"Ann Lab Med"},{"issue":"1","key":"10.1016\/j.jcrc.2025.155077_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13054-021-03471-2","article-title":"Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study","volume":"25","author":"Blet","year":"2021","journal-title":"Crit Care"},{"key":"10.1016\/j.jcrc.2025.155077_bb0040","doi-asserted-by":"crossref","first-page":"1058235","DOI":"10.3389\/fmed.2022.1058235","article-title":"Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: post-hoc analyses of the phase II adrenomedullin and outcome in septic shock 2 trial","volume":"9","author":"van Lier","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"10.1016\/j.jcrc.2025.155077_bb0045","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00134-021-06537-5","article-title":"Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial","volume":"47","author":"Laterre","year":"2021","journal-title":"Intensive Care Med"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944125000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944125000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T22:41:48Z","timestamp":1747953708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944125000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":9,"alternative-id":["S0883944125000644"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2025.155077","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enibarcimab for the treatment of septic shock in patients selected by a combination of the biomarkers bio-ADM and DPP3: A prespecified subgroup analysis of the AdrenOSS-2 trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2025.155077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"155077"}}